Stop flow analysis of aldosterone and steroidal antagonist SC-8109 on renal tubular sodium transport kinetics

Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease

The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age. All received digoxin and chlorothiazide. In addition, group A (n = 10) was given supplements of potassium and group B (n = 11) received spironolactone. Daily clinical observations of vital signs, weight, hepatomegaly, and vomiting were recorded. Paired t test analysis showed significant reduction in liver size and weight (P less than 0.01) and respiratory rate (P less than 0.05) in group B, and less significant decreases in group A. The incidence of vomiting was slightly lower in group B. We conclude that the addition of spironolactone hastens and enhances the response to standard treatment with digoxin and chlorothiazide in infants with congestive heart failure.

Changes of fractional renal clearance of magnesium after spironolactone administration in normal subjects

Spironolactone, 200 mg/24 hours, was administered for 4 days to 18 clinically healthy subjects and 10 hospitalised patients with normal renal function. Changes of fractional renal clearance of magnesium before and after spironolactone administration were studied in the first group. Corresponding changes of the ratio of renal clearance of potassium to renal clearance of magnesium were studied in the second group. After spironolactone administration, fractional clearance of magnesium showed a statistically significant decrease in relation to its values before spironolactone administration, while the ratio clearance of potassium/clearance of magnesium showed no statistically significant change. The results suggest that spironolactone administration decreases the renal excretion of magnesium and potassium in an equivalent manner.